Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1

Conditions

Neoplasms 2Spinal Cord Neoplasms 1Optic Nerve Glioma 1Oligodendroglioma 1Neoplasms by Histologic Type 1Meningioma 1Medulloblastoma 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Familial ependymoma 1Central Nervous System Neoplasms 1Breast Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × emvododstat × Clear all
NCT03761069 2022-02-02

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

PTC Therapeutics

Phase 1 Terminated
33 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute

NCT00704821 2019-05-10

PTC299 for Treatment of Advanced Cancer

PTC Therapeutics

Phase 1 Terminated
76 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡